Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C
Titel:
Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C
Auteur:
Price, T.J. Zannino, D. Wilson, K. Simes, R.J. Cassidy, J. Van Hazel, G.A. Robinson, B.A. Broad, A. Ganju, V. Ackland, S.P. Tebbutt, N.C.